Literature DB >> 9927724

Delta ribozyme has the ability to cleave in transan mRNA.

G Roy1, S Ananvoranich, J P Perreault.   

Abstract

We report here the first demonstration of the cleavage of an mRNA in trans by delta ribozyme derived from the antigenomic version of the human hepatitis delta virus (HDV). We characterized potential delta ribozyme cleavage sites within HDV mRNA sequence (i.e. C/UGN6), using oligonucleotide binding shift assays and ribonuclease H hydrolysis. Ribozymes were synthesized based on the structural data and then tested for their ability to cleave the mRNA. Of the nine ribozymes examined, three specifically cleaved a derivative HDV mRNA. All three active ribozymes gave consistent indications that they cleaved single-stranded regions. Kinetic characterization of the ability of ribozymes to cleave both the full-length mRNA and either wild-type or mutant small model substrate suggests: (i) delta ribozyme has turnovers, that is to say, several mRNA molecules can be successively cleaved by one ribozyme molecule; and (ii) the substrate specificity of delta ribozyme cleavage is not restricted to C/UGN6. Specifically, substrates with a higher guanosine residue content upstream of the cleavage site (i.e. positions -4 to -2) were always cleaved more efficiently than wild-type substrate. This work shows that delta ribozyme constitutes a potential catalytic RNA for further gene-inactivation therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927724      PMCID: PMC148271          DOI: 10.1093/nar/27.4.942

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  9 in total

1.  Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo.

Authors:  Dominique Lévesque; Sanaa Choufani; Jean-Pierre Perreault
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

2.  Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.

Authors:  Lucien Junior Bergeron; Jonathan Ouellet; Jean-Pierre Perreault
Journal:  Curr Med Chem       Date:  2003-12       Impact factor: 4.530

3.  Activity of HDV ribozymes to trans-cleave HCV RNA.

Authors:  Yue-Cheng Yu; Qing Mao; Chang-Hai Gu; Qi-Fen Li; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

4.  Gene targeting in the Gram-Positive bacterium Lactococcus lactis, using various delta ribozymes.

Authors:  Karine Fiola; Jean-Pierre Perreault; Benoit Cousineau
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

5.  Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus.

Authors:  Lucien Junior Bergeron; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

6.  Formation of the P1.1 pseudoknot is critical for both the cleavage activity and substrate specificity of an antigenomic trans-acting hepatitis delta ribozyme.

Authors:  Patrick Deschênes; Jonathan Ouellet; Jonathan Perreault; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2003-04-15       Impact factor: 16.971

7.  Catalytic cleavage of cis- and trans-acting antigenomic delta ribozymes in the presence of various divalent metal ions.

Authors:  J Wrzesinski; M Legiewicz; B Smólska; J Ciesiolka
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

8.  Inhibition of telomerase activity by HDV ribozyme in cancers.

Authors:  Yingying Lu; Junchao Gu; Dachuan Jin; Yanjing Gao; Mengbiao Yuan
Journal:  J Exp Clin Cancer Res       Date:  2011-01-06

9.  Target-dependent on/off switch increases ribozyme fidelity.

Authors:  Lucien Junior Bergeron; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2005-02-24       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.